TY - JOUR
T1 - The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease
AU - Strober, Warren
AU - Lúdvíksson, Björn R.
AU - Fuss, Ivan J.
PY - 1998/5/15
Y1 - 1998/5/15
N2 - In recent years, it has become apparent that overproduction of the Th1 cytokines interleukin-12 and interferon-γ is the probable driving force behind murine models of intestinal inflammation resembling Crohn disease and intestinal inflammation in humans with Crohn disease. In addition, studies of murine models strongly suggest that this overproduction is associated with inadequate secretion of the counter-regulatory and anti-inflammatory cytokine transforming growth factor-β. Thus, mucosal inflammation in models (and possibly in humans) may result from an imbalance between normally occurring positive (immunogenic or inflammatory) responses and negative (tolerogenic or anti-inflammatory) mucosal immune responses. These new findings and the hypotheses that arise from them are being used to construct new approaches to the treatment of Crohn disease that are based on the administration of anti- inflammatory cytokines and anticytokine antibodies.
AB - In recent years, it has become apparent that overproduction of the Th1 cytokines interleukin-12 and interferon-γ is the probable driving force behind murine models of intestinal inflammation resembling Crohn disease and intestinal inflammation in humans with Crohn disease. In addition, studies of murine models strongly suggest that this overproduction is associated with inadequate secretion of the counter-regulatory and anti-inflammatory cytokine transforming growth factor-β. Thus, mucosal inflammation in models (and possibly in humans) may result from an imbalance between normally occurring positive (immunogenic or inflammatory) responses and negative (tolerogenic or anti-inflammatory) mucosal immune responses. These new findings and the hypotheses that arise from them are being used to construct new approaches to the treatment of Crohn disease that are based on the administration of anti- inflammatory cytokines and anticytokine antibodies.
UR - http://www.scopus.com/inward/record.url?scp=0032524131&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-128-10-199805150-00009
DO - 10.7326/0003-4819-128-10-199805150-00009
M3 - Article
C2 - 9599198
AN - SCOPUS:0032524131
SN - 0003-4819
VL - 128
SP - 848
EP - 856
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 10
ER -